CA
NVAX icon

Cetera Advisors’s Novavax NVAX Stock Holding History

Cetera Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,572
Closed -$389K – 1425
2022
Q2 		$389K Sell
7,572
-60
-0.8% -$3.11K 0.01% 953
2022
Q1 		$562K Buy
7,632
+254
+3% +$22.6K 0.01% 830
2021
Q4 		$1.06M Buy
7,378
+346
+5% +$59.5K 0.02% 580
2021
Q3 		$1.46M Buy
7,032
+309
+5% +$68.1K 0.03% 491
2021
Q2 		$1.43M Buy
6,723
+433
+7% +$79.3K 0.03% 436
2021
Q1 		$1.14M Sell
6,290
-1,961
-24% -$391K 0.03% 440
2020
Q4 		$920K Buy
8,251
+141
+2% +$15K 0.03% 441
2020
Q3 		$879K Buy
8,110
+2,190
+37% +$267K 0.03% 402
2020
Q2 		$493K Buy
+5,920
New +$226K 0.02% 535
2019
Q2 		– Sell
-1,000
Closed -$11K – 1161
2019
Q1 		$11K Buy
+1,000
New +$31.6K ﹤0.01% 1131
2016
Q4 		– Sell
-750
Closed -$31K – 781
2016
Q3 		$31K Buy
+750
New +$96.8K ﹤0.01% 752

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Cetera Advisors's NVAX Position: Q3 2022 in Review

Cetera Advisors sold out of Novavax (NVAX) in Q3 2022, closing a stake of 7,572 shares — an estimated $389K sold.

Cetera Advisors first reported a position in NVAX in Q3 2016 and held it in 11 quarters. The position peaked at $1.46M in Q3 2021. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

  • Cetera Advisors reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
  • Cetera Advisors sold 7,572 Novavax shares in Q3 2022, an estimated $389K.
  • Cetera Advisors first reported a position in Novavax in Q3 2016 and held it in 11 quarters.
  • Cetera Advisors's Novavax position peaked at $1.46M in Q3 2021.
  • 253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Cetera Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.